Figure 4 | Scientific Reports

Figure 4

From: Novel benzofuran derivative DK-1014 attenuates lung inflammation via blocking of MAPK/AP-1 and AKT/mTOR signaling in vitro and in vivo

Figure 4

Airway inflammatory mice model and airway hyperresponsiveness in mice exposed to ovalbumin and DK-1014. Mice were sensitized with a 20-µg intraperitoneal injection of OVA in aluminium hydroxide in PBS on days 1 and 14: (a) airway challenge performed using an ultrasonic nebulizer that administered 30 mg/kg/day of DK-1014 or Montelukast on days 21, 22, and 23. (b) AHR indirectly assessed 24 h after the last challenge using single-chamber, whole-body plethysmography. NC = normal control mice treated with PBS only; OVA = ovalbumin-sensitized/challenged mice; Mon = ovalbumin sensitized/challenged mice treated with montelukast (30 mg/kg); DK-1014 = ovalbumin sensitized/challenged mice treated with DK-1014 (30 mg/kg). ##p < 0.005 compared with the normal control; *p < 0.05 and **p < 0.005 compared to OVA mice.

Back to article page